Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

eHealth Africa Academy has graduated 92 students across Nigeria and Africa, building their capacities in advanced javascript and data analytics. The organisation said this was part of its goal to ...

School of Advanced Materials Science and Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea ...

According to @demishassabis on Bloomberg Tech Europe, Isomorphic Labs is leveraging artificial intelligence to design new drug candidates that address challenging medical targets. The discussion with ...

WhatsApp has introduced Advanced Chat Privacy, a feature that builds on its end-to-end encryption to keep your messages as private as possible by keeping chats in the ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. As Isomorphic Labs aims its artificial ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...